natgillin/translations-raw huggingface dataset:
No interaction studies have been performed with NovoEight.
Študij medsebojnega delovanja pri zdravilu NovoEight niso izvedli.
No interaction studies have been performed with Nuwiq.
Študij medsebojnega delovanja zdravila Nuwiq z drugimi zdravili niso izvedli.
No interaction studies have been performed with oral contraceptives containing other progestogens, however an effect of Tecfidera on their exposure is not expected.
S peroralnimi kontraceptivi, ki vsebujejo druge progestogene, niso opravili študij medsebojnega delovanja, vendar ne pričakujemo učinka zdravila Tecfidera na izpostavljenost drugim kontraceptivom.
No interaction studies have been performed with Provenge.
Študij medsebojnega delovanja z zdravilom Provenge niso izvedli.
No interaction studies have been performed.
Raziskav o interakcijah z zdravilom Beromun niso izvajali.
No interaction studies have been performed.
Raziskav o medsebojnem delovanju niso izvedli.
No interaction studies have been performed.
Študij medsebojnega delovanja niso izvedli, vključno s imunosupresivnimi zdravili.
No interaction studies in humans have been performed.
Študij medsebojnega delovanja pri človeku niso izvedli.
No interaction studies of Lutetium (177Lu) with other medicinal products have been performed.
Študij medsebojnega delovanja lutecija (177Lu) z drugimi zdravili niso izvedli.
No interaction studies of Yttrium (90Y) chloride with other medicinal products have been performed, because Yttriga is a precursor solution for radiolabelling medicinal products.
Študij medsebojnega delovanja itrijevega (90Y) klorida z drugimi zdravili niso izvedli, ker je Yttriga raztopina radiofarmacevtskega predhodnika za radioaktivno označevanje zdravil.
No interaction studies with ELOCTA have been performed.
Študij medsebojnega delovanja z zdravilom ELOCTA niso izvedli.
No interaction studies with other medicinal products have been done.
Študij medsebojnega delovanja z drugimi zdravili niso izvedli.
No interaction studies with other vaccines or medicinal products have been performed.
Študij medsebojnega delovanja z drugimi cepivi ali zdravili niso izvedli.
No interaction study
Mehanizem ni znan.
No interaction study
Ni raziskave o medsebojnem
No interaction study
Ni raziskave o medsebojnem delovanju.
No interaction study
Ni raziskave o njihovem
No interaction study
Ni raziskave o njunem
No interaction study performed
Ni raziskave o medsebojnem delovanju.
No interaction study performed
Ni raziskave o njegovem medsebojnem delovanju.
No interaction study performed
niso izvajali.
No interaction study performed
Raziskav o interakcijah niso izvajali.
No interaction study performed
Raziskave o interakcijah niso izvajali.
No interaction study performed
Raziskave o interakciji niso izvajali.
No interaction study performed
Za sočasno uporabo z zdravilom
No interaction study performed
Študij medsebojnega delovanja niso izvedli.
No interaction was observed between dronedarone and losartan and an interaction between dronedarone and other AIIRAs is not expected.
Medsebojnih delovanj med dronedaronom in losartanom niso opazili in medsebojnih delovanj med dronedaronom in drugimi antagonisti receptorjev angiotenzina II ni pričakovati.
No interaction was observed between dronedarone and metformin, an OCT1 and OCT2 substrate.
Medsebojnega delovanja med dronedaronom in metforminom, substratoma OCT1 in OCT2, niso opazili.
No interaction was observed when busulfan was combined with fluconazole (antifungal agent) or 5 HT3 antiemetics such as ondansetron or granisetron.
Ko so busulfan kombinirali z flukonazolom (protiglivična učinkovina) ali 5-HT3-antiemetiki, kot sta ondansetron ali granisetron, niso opazili interakcij.
No interaction was seen when Cosentyx was administered concomitantly with methotrexate (MTX) and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis).
Pri uporabi zdravila Cosentyx sočasno z metotreksatom in/ali kortikosteroidi v študijah artritisa (med drugim pri bolnikih s psoriatičnim artritisom oziroma ankilozirajočim spondilitisom) niso opažali nobenih interakcij.
No interaction with other medicinal products and other forms of interaction are known.
Medsebojno delovanje s katerimkoli drugim zdravilom za uporabo v veterinarski medicini in ostale oblike medsebojnega delovanja niso znane.
No interactions
Brez interakcij
No interactions
Zdravila brez interakcij z zdravilom Rasilez
No interactions
Zdravila brez interakcij z zdravilom Riprazo
No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/mL) following ocular dosing with bimatoprost 0.3 mg/mL eye drops, solution (multi-dose formulation).
Ker je sistemska koncentracija bimatoprosta pri lokalni uporabi bimatoprosta 0,3 mg/ml kapljic za oko, raztopine (večodmerna oblika), na očeh izjemno nizka (manj kot 0,2 ng/ml), interakcij pri ljudeh ni pričakovati.
No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing with bimatoprost 0.3 mg/ml eye drops, solution.
Ker je sistemska koncentracija bimatoprosta pri lokalni uporabi bimatoprosta 0,3 mg/ml kapljic za oko, raztopine, na očeh izjemno nizka (manj kot 0,2 ng/ml), interakcij pri ljudeh ni pričakovati.
No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing with bimatoprost 0.3 mg/ml eye drops, solution.
Ker je sistemska koncentracija bimatoprosta pri lokalni uporabi bimatoprosta, 0,3 mg/ml kapljic za oko, raztopine, na očeh izjemno nizka (manj kot 0,2 ng/ml), interakcij pri ljudeh ni pričakovati.
No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.
Ne prihaja do medsebojnega delovanja zdravila Advocate z drugimi običajnimi pripravki za uporabo v veterinarski medicini.
No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.
Ne prihaja do medsebojnega delovanja zdravila Advocate z drugimi rutinsko dajanimi zdravili za uporabo v veterinarski medicini ali kirurškimi posegi.
No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.
Pri sočasni uporabi zdravila Advocate z ostalimi rutinsko uporabljanimi zdravili za uporabo v veterinarski medicini ali pri medicinskih in kirurških postopkih, ni bilo nobenih interakcij.
No interactions of human coagulation factor IX (rDNA) products with other medicinal products have been reported.
Medsebojna delovanja pripravkov humanega koagulacijskega faktorja IX (rDNA) z drugimi zdravili niso znana.
No interactions of KOGENATE Bayer with other medicinal products have been reported.
O medsebojnem delovanju zdravila KOGENATE Bayer z drugimi zdravili ni poročil.
No interactions of Nonafact with other medicinal products are known.
Ni znanih medsebojnih interakcij med zdravilom Nonafact in drugimi zdravili.
No interactions of Yttrium (90Y) chloride with other medicinal products are known because no studies have investigated this issue.
Ne poznamo nobenih interakcij itrijevega (90Y) klorida z drugimi zdravili, ker s tem v zvezi niso opravili nobene študije.
No interactions were observed between sildenafil (100 mg single oral dose) and acenocoumarol.
Med sildenafilom (posamičen peroralni odmerek 100 mg) in acenokumarolom niso opazili nobenih interakcij.
No interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan, phenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS), nifedipine slow release, sibutramine or alcohol have been observed.
Interakcij z amitriptilinom, atorvastatinom, bigvanidi, digoksinom, fibrati, fluoksetinom, losartanom, fenitoinom, fenterminom, pravastatinom, nifedipin gastrointestinalnim terapevtskim sistemom (GITS), s pripravki nifedipina z upočasnjenim sproščanjem, sibutraminom ali z alkoholom niso opazili.
No interactions with other medicinal products are currently known.
Doslej ni znano nobeno medsebojno delovanje tega zdravila z drugimi zdravili.
No interference observed
Motnja ni opažena
No interruption b
ni prekinitve b
No intracranial bleeding or gastrointestinal haemorrhage events were reported in patients receiving Jakavi.
Pri bolnikih, ki so prejemali zdravilo Jakavi, niso poročali o nobenem primeru intrakranialne ali gastrointestinalne krvavitve.
No investigations on fertility have been conducted.
Študij o vplivu na sposobnost razmnoževanja niso izvedli.
No investigations on fertility have been performed (see section 5.3).
Raziskave o plodnosti niso bile izvedene (glejte poglavje 5.3).
No Lamivudine/Zidovudine Teva dosage adjustment necessary, unless patient has renal impairment (See Section 4.2).
Teva ni potrebna, razen če ima bolnik okvaro ledvic (glejte poglavje 4.2).
No light
lučka ne sveti
No line listings are required – these can be provided in signal evaluation reports as necessary.
Vrstični seznami niso zahtevani – če je potrebno, se jih lahko predloži v poročilih vrednotenja signalov.
No liver metastases: ALT/AST ≤3 x ULN
Brez metastaz jeter: ALT/AST ≤ 3 x ULN
No local irritation of the blood vessel was observed after i.v. or paravenous administration of idarucizumab.
Lokalnega draženja krvnih žil po intravenskem ali paravenskem dajanju idarucizumaba niso opazili.
No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin.
Dolgoročne študije za oceno kancerogenega potenciala enoksaparina na živalih niso bile izvedene.
No long-term studies in animals have been performed to evaluate the carcinogenic potential.
Dolgoročne študije pri živalih za oceno karcinogenega potenciala niso bile izvedene.
no longer authorised no longer authorised
ā dovoljenja za promet ā dovoljenja za promet
No loss of anticonvulsant efficacy (tolerance development) during continuous treatment of 4 weeks was observed in experimental studies lasting 4 weeks.
Po stalnem 4-tedenskem zdravljenju v 4-tedenskih eksperimentalnih študijah niso opazili izgube protikonvulzivnega učinka (razvoja tolerance).
No loss of anticonvulsant efficacy (tolerance development) during continuous treatment of 4 weeks were observed in experimental studies lasting 4 weeks.
Po stalnem 4-tedenskem zdravljenju v 4-tedenskih eksperimentalnih študijah niso opazili izgube protikonvulzivnega učinka (razvoja tolerance).
No Lynparza dose adjustment is required for patients with mild renal impairment.
Odmerka zdravila Lynparza pri bolnicah z blago okvaro ledvic ni treba prilagoditi.
No malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a Humira trial in paediatric patients with chronic plaque psoriasis.
Pri 77 pediatričnih bolnikih v preskušanju zdravila Humira pri pediatričnih bolnikih s kronično psoriazo v plakih z izpostavljenostjo 80,0 bolnikov-let, niso opazili malignomov.
No maternal or embryofoetal effects of treatment were observed in reproductive studies in rats at dose levels up to 28-times the recommended human dose (1000 Units) based on an average adult body weight of 70 kg.
V retrospektivnih študijah na podganah pri odmerkih, ki so bili 28-krat večji od priporočenega odmerka za ljudi (1000 enot) na podlagi povprečne odrasle telesne mase 70 kg, niso opazili učinkov zdravljenja na mater, zarodek ali plod.
No matter what day this happens, continue with the same twice-a-week schedule for your next patch, even if it means changing the new patch before 3 to 4 days have elapsed.
Ne glede na to, kateri dan se to zgodi, se držite vašega urnika nanosa dvakrat tedensko za naslednji obliž, četudi to pomeni, da ga boste morali zamenjati preden pretečejo 3 ali 4 dnevi.
No matter what day this happens, continue with the twice-a-week schedule that you have marked on your patch box.
Ne glede na to, kateri dan se to zgodi, se držite vašega urnika nanosa dvakrat tedensko, kot ste označili na škatlici.
No maximum tolerated dose of sunitinib has been identified for this patient population due to dose limiting toxicities (see section 5.1).
Za to populacijo bolnikov največji odmerek sunitiniba, ki ga bolniki še prenašajo, zaradi toksičnih učinkov, ki so omejevali odmerek, ni bil ugotovljen (glejte poglavje 5.1).
No meaningful changes in blood pressure, heart rate with pseudoephedrine were observed in the healthy volunteers, and no clinically relevant increase in tyramine sensitivity were observed.
Opazili niso ne pomembnih sprememb krvnega tlaka ali srčnega utripa pri uporabi psevdoefedrina pri zdravih prostovoljcih ne klinično pomembnega povečanja občutljivosti za tiramin.
No meaningful clinical data on exposure during pregnancy are available.
Pomembnih podatkov o izpostavljenosti med nosečnostjo ni.
No meaningful gender differences have been observed.
Pomembnih razlik zaradi spola niso opazili.
No MedDRA 17.1 PT was retrieved.
V MedDRA 17.1 ni prednostnega izraza (PT – Preferred Term).
No metabolites of telbivudine were detected following administration of 14C-telbivudine in humans.
Pri ljudeh niso odkrili presnovkov telbivudina po aplikaciji 14C-telbivudina.
No more doses can be delivered after this and IONSYS will be removed by your doctor or nurse.
Potem ni več mogoče sprožiti odmerjanja in sistem IONSYS mora odstraniti zdravnik ali medicinska sestra.
No more than 2 doses should be given within 24 hours.
V 24 urah ne smete prejeti več kot 2 odmerka.
No more than 3 attempts per affected joint are recommended to disrupt a cord.
Več kot trije poskusi prekinitve vozliča na prizadeti sklep niso priporočljivi.
No more than 3 injections of Firazyr should be administered in a 24 hour period.
V 24-urnem obdobju se smejo dati največ 3 injekcije zdravila Firazyr.
No more than three 27 mg tablets should be taken in 24 hours.
V 24-urah bolnik ne sme vzeti več kakor tri 27-mg tablete.
No more than three 60 mg capsules should be taken in 24 hours.
V 24-urah bolnik ne sme vzeti več kakor tri 60-mg kapsule.
No more than two courses of Eurartesim may be given within a 12 month period (see sections 4.4 and 5.3).
V 12-mesečnem obdobju se bolnika ne sme zdraviti z zdravilom Eurartesim več kot dvakrat (glejte poglavji 4.4 in 5.3).
No mortality was observed in rats or dogs following single oral doses of 2000 mg/kg (maximum feasible dose).
Smrtnosti pri podganah ali psih po enkratnih peroralnih odmerkih 2000 mg/kg (največji razumni odmerek) ni bilo.
No MRL
MRL ni zahtevan
No mutation
ni mutacije
No natural rubber latex has to date been detected in the removable needle cap.
Do sedaj v snemljivi zaporki na igli niso zaznali naravne lateksne gume.
No Nausea (Likert Scale) p-value c
Brez slabosti (Likertova lestvica)
No Nausea (Likert Scale) p-value c
Brez slabosti (Likertova lestvica) p-vrednostc
No needle, intravenous tubing or any other device for parenteral administration should be attached to the oral syringe.
Na brizgo za peroralno dajanje ne smejo biti pritrjene igle, intravenski infuzijski sistemi ali katere koli druge naprave za parenteralno dajanje.
No needle, intravenous tubing or any other device for parenteral administration should be attached to the oral syringe.
Na peroralno brizgo ne priključite igle, intravenske cevke ali drugih pripomočkov za parenteralno dajanje.
No needles are involved in the preparation of EVICEL for administration.
Pri pripravi zdravila EVICEL za uporabo ne potrebujete injekcijskih igel.
No neutropenia at baseline
Brez nevtropenije na začetku
No new adverse drug reactions were identified with the addition of Incruse to FF/VI in these studies.
V teh študijah niso ugotovili novih neželenih učinkov med uporabo zdravila Incruse ob FF/VI.
No New ENF*
Brez ENF
No new events of progression to AP/BC were reported on-treatment since the 2-year analysis.
Od analize po 2 letih dalje niso poročali o nobenem novem primeru napredovanja v pospešeno fazo oziroma blastno krizo.
No new events of progressions to AP/BC were reported on-treatment since the 2-year analysis.
Od analize po 2 letih dalje niso poročali o nobenem novem primeru napredovanja v pospešeno fazo oziroma blastno krizo.
No new safety concerns were observed when Bortezomib Accord was added to the standard pediatric pre B cell ALL chemotherapy backbone.
Pri dodatku zdravila Bortezomib Accord standardni pediatrični pre B-celični ALL osnovni kemoterapevtski shemi niso opazili novih vplivov na varnost.
No new safety concerns were observed when bortezomib was added to the standard paediatric pre B cell ALL chemotherapy backbone.
Pri dodatku bortezomiba standardni pediatrični pre B-celični ALL osnovni kemoterapevtski shemi niso opazili novih vplivov na varnost.
No new safety concerns were observed when VELCADE was added to the standard pediatric pre B cell ALL chemotherapy backbone.
Pri dodatku zdravila VELCADE standardni pediatrični pre B-celični ALL osnovni kemoterapevtski shemi niso opazili novih vplivov na varnost.
No new safety findings were observed.
Novih z varnostjo povezanih ugotovitev ni bilo.
No new safety signals have been identified in patients exposed to 0.05 mg/kg/day of Revestive for up to 30 months in a long-term open-label extension study.
Pri bolnikih, ki so bili do 30 mesecev vključeni v dolgoročno odprto podaljšano študijo in so prejemali odmerek 0,05 mg/kg/dan zdravila Revestive, niso opazili nobenih novih varnostnih signalov.
No new unexpected safety signals were observed in this trial.
V tem preskušanju niso ugotovili nobenih novih nepričakovanih varnostnih signalov.
no no
dravilo
no no
ve ve
No non-specific tissue cross-reactivity was demonstrated when canakinumab was applied to normal human tissues.
Pri uporabi kanakinumaba na normalnih človeških tkivih ni prišlo do nespecifične navzkrižne reaktivnosti s tkivi.
No non-specific tissue cross-reactivity was observed when secukinumab was applied to normal human tissue.
Ko so sekukinumab aplicirali na normalno človeško tkivo, niso opažali nespecifične navzkrižne reaktivnosti s tkivom.
No NOTEL (No Observed Toxic Effect Level) could be established in the preclinical studies with the exception of a 7-day administration of 0.1 µg/kg in monkeys.
Ravni, pri kateri ni zaslediti toksičnega učinka, v predkliničnih raziskavah niso mogli določiti, z izjemo 7-dnevnega dajanja odmerkov po 0,1 µg/kg pri opicah.
No NS5B nucleoside inhibitor (NI) RAVs were observed at failure in the 2 patients.
Pri teh dveh bolnikih niso zabeležili nobene različice, povezane z odpornostjo na nukleozidne zaviralce NS5B (RAV NI NS5B; NI – nucleoside inhibitor) ob neuspehu.
no oduct no oduct
enja enja
No of
št.
No of patients included in the analysis No. (%) of patients with event
Število bolnikov, vključenih v analizo
No of positive
št. pozitivnih
No of positive nodes
št. pozitivnih bezgavk
No other adverse effects other than those mentioned under section 6 (Adverse reactions) have been observed after administration of a 10-fold overdose of the vaccine.
Po dajanju prevelikega odmerka cepiva ni bilo opaziti drugih neželenih učinkov, razen tistih, navedenih v poglavju 6 (Neželeni učinki).
No other adverse effects other than those mentioned under “Adverse reactions” have been observed after administration of a 10-fold overdose of the vaccine.
Po dajanju prevelikega odmerka cepiva ni bilo opaziti drugih neželenih učinkov, razen tistih, navedenih v poglavju 6 (Neželeni učinki).
No other adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed.
Drugi neželeni učinki, razen tistih, ki so navedeni v poglavju ‘Neželeni učinki’, niso bili opaženi.
No other adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed.
Drugi neželeni učinki, razen tistih, ki so navedeni v ‘Neželeni učinki’, niso bili opaženi.
No other adverse reactions other than those mentioned under “Adverse reactions” were observed after administration of a 10-fold overdose of the vaccine.
Po dajanju prevelikega odmerka cepiva ni bilo opaziti drugih neželenih učinkov, razen tistih, navedenih v poglavju 6 (Neželeni učinki).
No other clinically significant drug interaction has been reported during follitropin alfa therapy.
Med zdravljenjem s folitropinom alfa niso poročali o drugih klinično pomembnih interakcijah z zdravili.
No other findings, in the above toxicity studies, provide information of significant relevance to clinical use.
Omenjene študije toksičnosti niso pokazale drugih za klinično uporabo pomembnih informacij.
No other formal DDI studies with olaratumab and medicinal products commonly used in cancer patients, including those with STS (e.g. antiemetics, analgesics, anti-diarrheal drugs, oral contraceptives, etc.), have been performed.
Druge formalne študije medsebojnega delovanja olarazumaba in zdravil, ki se pogosto uporabljajo pri bolnikih z rakom, vključno z sarkomom mehkih tkiv (npr. antiemetiki, analgetiki, antidiaroiki, peroralni kontraceptivi idr.), niso bile izvedene.
No other liquids should be used.
Ne uporabljajte drugih tekočin.
No other liquids, including grapefruit juice, should be used for dilution.
Drugih tekočin, še posebno pa soka grenivke, ne smemo uporabljati za redčenje.
No other medicines should be added to the solution containing Raptiva and Raptiva should not be reconstituted with other solvents.
Nobenih drugih zdravil ne smete dodajati v raztopino z zdravilom Raptiva in zdravila Raptiva ne smete rekonstituirati z drugimi vehikli.
No other medicines should be injected through the line reserved for Rapilysin, either at the same time, or before or after Rapilysin injection.
Skozi kanal, rezerviran za zdravilo Rapilysin, naj se ne injicira nobenega drugega zdravila, ne sočasno, ne pred injiciranjem zdravila Rapilysin ali po njem.
No other patient tested positive for anti-siltuximab antibodies and this results in an incidence rate of 0.2% for the 411 evaluable patients.
Pri nobenem drugem bolniku izvid prisotnosti protiteles proti siltuksimabu ni bil pozitiven, kar pri 411%bolnikih pomeni 0,2% stopnjo pojavnosti.
No other solutions should be used for reconstitution (see section 6.2).
Za pripravo se ne sme uporabljati drugih raztopin (glejte poglavje 6.2).
No other source of drinking water should be available during the medication period.
V času zdravljenja puranom ne sme biti na voljo noben drug vir pitne vode.
No other treatment­related tumours have been found.
Drugih tumorjev, povezanih z zdravljenjem s tem zdravilom, niso ugotovili.
No other vaccines/ medicinal products, including oral polio vaccine and antimalarials, have been given simultaneously with Dukoral in clinical studies.
V kliničnih študijah niso skupaj z Dukoralom dajali nobenega drugega cepiva ali zdravila, vključno s cepivom proti otroški paralizi in z antimalariki.
No overall clinically relevant adverse impact in paediatric patients aged 6 to 17 years was observed after treatment with aliskiren for up to one year based on neurocognitive and developmental assessment.
Pri pediatričnih bolnikih, starih 6 do 17 let, po zdravljenju, ki je trajalo do eno leto, niso opažali klinično pomembnega neželenega vpliva aliskirena na rezultate nevrokognitivnih in razvojnih testov.
No overall clinically relevant adverse impact on paediatric patients aged 6 to 17 years was observed after treatment with aliskiren for up to one year based on neurocognitive and developmental assessment.
Pri pediatričnih bolnikih, starih 6 do 17 let, po zdravljenju, ki je trajalo do eno leto, niso opažali klinično pomembnega neželenega vpliva aliskirena na rezultate nevrokognitivnih in razvojnih testov.
No overall differences in effectiveness were observed between patients over 65 years and younger adult patients.
V celoti niso ugotovili razlik v učinkovitosti med bolniki, starejšimi od 65 let, in mlajšimi odraslimi bolniki.
No overall differences in safety of Zurampic were observed in patients with mild or moderate renal impairment (eCrCL of 30-89 mL/min) compared to patients with normal renal function (see sections 4.2 and 5.2).
Pri bolnikih z blago ali zmerno ledvično okvaro (ocenjeni očistek kreatinina od 30 do 89 ml/min) na splošno niso ugotovili razlik v varnosti zdravila Zurampic v primerjavi z bolniki z normalnim delovanjem ledvic (glejte poglavji 4.2 in 5.2).